RE:RE:RE:RE:RE:RE:RE:Big Pharma walks away from gene-therapy biotech Sarepta's only placebo-controlled, randomized data company came from part 1 of phase 2 trial 102, which did not show a statistically significant improvement in treated patients as measured by a motor function scale.
Yet the company was given a 'thumbs up' by the FDA's Advisory Committee and is trading at US$150 per share today.